Clinical data evaluating CAL-101 in patients with hematologic malignancies to be presented at ASCO 2010

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that updated clinical data evaluating CAL-101, an oral, PI3K inhibitor, in patients with hematologic malignancies, will be presented during a poster discussion session at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 4-8, 2010 at McCormick Place in Chicago, IL.

Presentation details:

Interim Results from a Phase I Study of CAL-101, a Selective Oral Inhibitor of Phosphatidylinositol 3-Kinase p110δ Isoform, in Patients with Relapsed or Refractory Hematologic Malignancies

• Poster Discussion Session: Developmental Therapeutics
• Sunday, June 6, 2010, 2:00 p.m. to 6 p.m., with poster discussion from 5:00 p.m. to 6:00 p.m.
• Location: E405b, with discussion in E Hall D2
• Presenter: Richard R. Furman, M.D., Weill Cornell Medical College, New York, NY
• Abstract #3032

CAL-101 is a first-in-class inhibitor of the PI3K delta isoform. It is an orally administered small molecule, and exhibits a greater than 200-fold selectivity in cell-based assays for the delta isoform as compared to other class 1 PI3K isoforms. CAL-101 is designed to induce cancer cell death (apoptosis) and to inhibit the signaling pathways associated with cancer cell dependence on the tumor microenvironment.

SOURCE Calistoga Pharmaceuticals, Inc.